Jabbour, E <br/><br/>
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.  [electronic resource] 

 -  Leukemia  Jan 2010 
 - 6-12 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2009.193  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Benzamides<br/>Dasatinib<br/>Drug Resistance, Neoplasm<br/>Fusion Proteins, bcr-abl--genetics<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Mutation<br/>Piperazines--adverse effects<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrimidines--adverse effects<br/>Thiazoles--therapeutic use